Tempus AI Shares Slide 12% as Q4 Results Disappoint

Investing

02-25

Tempus AI reported fourth quarter results Monday, following which shares were down 12% in after-hours trading.

The artificial intelligence-powered precision medicine company posted revenue of $200.7 million for the quarter ended December 31, 2024, up 35.8% YoY . Adjusted loss per share came in at $0.18, narrower than the $1.58 loss reported in the same quarter last year.

Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 44.6% to $80.2 million.

"Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to show strong volume growth and our Data business delivered record results throughout the year," said Eric Lefkofsky, Founder and CEO of Tempus.

For the full year 2025, Tempus expects revenue of approximately $1.24 billion, representing 79% annual growth. The company also anticipates achieving positive adjusted EBITDA of $5 million in 2025, an improvement of about $110 million over 2024.

Tempus ended 2024 with $940 million in total remaining contract value and 140% net revenue retention. The company completed its acquisition of Ambry Genetics on February 3, 2025.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1161962625"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161962625\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1161962625?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 07:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161962625","market":"us","top_or_hot":-1,"title":"Tempus AI Shares Slide 12% as Q4 Results Disappoint","media":"Investing","content":"<html><head></head><body><p> <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> reported fourth quarter results Monday, following which shares were down 12% in after-hours trading.</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/f15d2734141482e6aab6365f7e340444\" tg-height=\"392\" tg-width=\"415\"/></p><p style=\"text-align: start;\">The artificial intelligence-powered precision medicine company posted revenue of $200.7 million for the quarter ended December 31, 2024, up 35.8% YoY . Adjusted loss per share came in at $0.18, narrower than the $1.58 loss reported in the same quarter last year.</p><p style=\"text-align: start;\">Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 44.6% to $80.2 million.</p><p style=\"text-align: start;\">\"Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to show strong volume growth and our Data business delivered record results throughout the year,\" said Eric Lefkofsky, Founder and CEO of Tempus.</p><p style=\"text-align: start;\">For the full year 2025, Tempus expects revenue of approximately $1.24 billion, representing 79% annual growth. The company also anticipates achieving positive adjusted EBITDA of $5 million in 2025, an improvement of about $110 million over 2024.</p><p style=\"text-align: start;\">Tempus ended 2024 with $940 million in total remaining contract value and 140% net revenue retention. The company completed its acquisition of Ambry Genetics on February 3, 2025.</p></body></html>","source":"hk_investing_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Tempus AI Shares Slide 12% as Q4 Results Disappoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI Shares Slide 12% as Q4 Results Disappoint\n</h2>\n<h4 class=\"meta\">\n\n\n2025-02-25 07:28 GMT+8   <a href=\"https://www.investing.com/news/earnings/tempus-ai-shares-slide-7-as-q4-results-disappoint-93CH-3887329\"><strong>Investing</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Tempus AI reported fourth quarter results Monday, following which shares were down 12% in after-hours trading.The artificial intelligence-powered precision medicine company posted revenue of $200.7 ...</p>\n<a href=\"https://www.investing.com/news/earnings/tempus-ai-shares-slide-7-as-q4-results-disappoint-93CH-3887329\">网页链接</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"https://www.investing.com/news/earnings/tempus-ai-shares-slide-7-as-q4-results-disappoint-93CH-3887329","article_id":"1161962625","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161962625","pubTimestamp":1740439713,"columns":[],"sourceInfo":{"source_id":"hk_investing_stock","name":"Investing"},"weMediaInfo":null,"summary":"$Tempus AI$ reported fourth quarter results Monday, following which shares were down 12% in after-hours trading.The artificial intelligence-powered precision medicine company posted revenue of $200.7 million for the quarter ended December 31, 2024, up 35.8% YoY . Adjusted loss per share came in at $0.18, narrower than the $1.58 loss reported in the same quarter last year.Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 4","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI"},"translate_title":"第四季度业绩令人失望，Tempus AI股价下跌12%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1.1},"content_text":"Tempus AI reported fourth quarter results Monday, following which shares were down 12% in after-hours trading.The artificial intelligence-powered precision medicine company posted revenue of $200.7 million for the quarter ended December 31, 2024, up 35.8% YoY . Adjusted loss per share came in at $0.18, narrower than the $1.58 loss reported in the same quarter last year.Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 44.6% to $80.2 million.\"Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to show strong volume growth and our Data business delivered record results throughout the year,\" said Eric Lefkofsky, Founder and CEO of Tempus.For the full year 2025, Tempus expects revenue of approximately $1.24 billion, representing 79% annual growth. The company also anticipates achieving positive adjusted EBITDA of $5 million in 2025, an improvement of about $110 million over 2024.Tempus ended 2024 with $940 million in total remaining contract value and 140% net revenue retention. The company completed its acquisition of Ambry Genetics on February 3, 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0}}}